Seclidemstat

Seclidemstat
Clinical data
Other names	SP-2577
Drug class	LSD1 inhibitor
Identifiers
	IUPAC name N-[(E)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide;
CAS Number	1423715-37-0;
PubChem CID	135565033;
ChemSpider	64853793;
UNII	TYH386V3WJ;
KEGG	D12577;
ChEMBL	ChEMBL4297641;
Chemical and physical data
Formula	C20H23ClN4O4S
Molar mass	450.94 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C/C(=N\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)/C3=C(C=CC(=C3)Cl)O;
	InChI InChI=InChI=1S/C20H23ClN4O4S/c1-14(18-13-16(21)6-7-19(18)26)22-23-20(27)15-4-3-5-17(12-15)30(28,29)25-10-8-24(2)9-11-25/h3-7,12-13,26H,8-11H2,1-2H3,(H,23,27)/b22-14+; Key:MVSQDUZRRVBYLA-HYARGMPZSA-N;

Seclidemstat is an investigational new drug that is being evaluated for the treatment of cancer.^[1] It is non-covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1, KDM1A) investigated for cancer therapy, including Ewing sarcoma, SWI/SNF-mutated ovarian cancers, and advanced solid tumors. By blocking both the enzymatic and scaffolding functions of LSD1, especially its interactions within transcriptional regulatory complexes such as CoREST, Seclidemstat reprograms gene expression patterns that sustain tumor proliferation and immune evasion. It is among the handful of LSD1 inhibitors to reach clinical trials, with research focusing on its anticancer activity and potential immune modulatory effects in the tumor microenvironment. Ongoing challenges in development have included both efficacy and safety in early-phase studies as identified across the class of LSD1 inhibitors.^[2]